HC Wainwright set a $126.00 price target on AnaptysBio (NASDAQ:ANAB) in a research report sent to investors on Monday, Stock Target Advisor reports. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other equities analysts have also recently commented on the company. Stifel Nicolaus set a $124.00 target price on AnaptysBio and gave the company a buy rating in a report on Tuesday, April 2nd. Wedbush restated an outperform rating on shares of AnaptysBio in a report on Friday, March 1st. Cantor Fitzgerald restated a buy rating and set a $140.00 target price on shares of AnaptysBio in a report on Wednesday, February 27th. Zacks Investment Research upgraded AnaptysBio from a sell rating to a buy rating and set a $77.00 target price for the company in a report on Wednesday, March 6th. Finally, Credit Suisse Group cut AnaptysBio from an outperform rating to a neutral rating and decreased their price objective for the company from $137.00 to $79.00 in a research note on Friday, June 21st. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company currently has an average rating of Buy and an average price target of $111.25.
Shares of AnaptysBio stock opened at $53.76 on Monday. The firm’s 50-day moving average price is $70.56. AnaptysBio has a 12 month low of $52.93 and a 12 month high of $110.00. The stock has a market cap of $1.45 billion, a PE ratio of -21.50 and a beta of 1.98.
AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. Equities analysts forecast that AnaptysBio will post -3.76 EPS for the current fiscal year.
In other news, CEO Hamza Suria sold 22,428 shares of AnaptysBio stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $73.76, for a total value of $1,654,289.28. Following the completion of the transaction, the chief executive officer now owns 31,524 shares in the company, valued at approximately $2,325,210.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Marco Londei sold 10,060 shares of AnaptysBio stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $73.06, for a total value of $734,983.60. Following the completion of the transaction, the insider now owns 32,437 shares of the company’s stock, valued at approximately $2,369,847.22. The disclosure for this sale can be found here. Company insiders own 14.00% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in ANAB. Tekla Capital Management LLC raised its position in shares of AnaptysBio by 43.4% during the 4th quarter. Tekla Capital Management LLC now owns 65,845 shares of the biotechnology company’s stock worth $4,200,000 after acquiring an additional 19,935 shares in the last quarter. FMR LLC raised its position in shares of AnaptysBio by 2.0% during the 4th quarter. FMR LLC now owns 4,012,735 shares of the biotechnology company’s stock worth $255,973,000 after acquiring an additional 77,268 shares in the last quarter. Millennium Management LLC raised its position in shares of AnaptysBio by 11,829.2% during the 4th quarter. Millennium Management LLC now owns 258,624 shares of the biotechnology company’s stock worth $16,498,000 after acquiring an additional 256,456 shares in the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of AnaptysBio by 7.2% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 10,007 shares of the biotechnology company’s stock worth $638,000 after acquiring an additional 674 shares in the last quarter. Finally, Deutsche Bank AG raised its position in shares of AnaptysBio by 94.6% during the 4th quarter. Deutsche Bank AG now owns 74,864 shares of the biotechnology company’s stock worth $4,774,000 after acquiring an additional 36,395 shares in the last quarter.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.
Featured Story: P/E Growth (PEG)
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.